الأصول تغيير تاريخ
AstraZeneca USD 114.02B 59M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
GRIFOLS EUR 20.08B 366M 2026-03
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lakefront Biotherapeutics EUR 3.37B 34.09M 2026-03
Qiagen NV USD 6.3B 257.54M 2025-12
UCB EUR 18.16B 971M 2025-12